GlassScriptPhysician profile
Imad Khreim
NPI 1104842731
$5,200.03
in general payments reported to CMS, 2019-2025
18 companies · $688 in 2025
The $688 reported for 2025 was more than what 75% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $697 · 2020: $631 · 2021: $700 · 2022: $907 · 2023: $899 · 2024: $678 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,182 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,182.41 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $852.04 | 2019-2025 | Rexulti |
| Abbvie INC. | $713.98 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $523.69 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $492.08 | 2019-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $471.00 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $467.49 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $435.16 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $430.07 | 2020-2025 | Austedo Xr, Austedo Xr |
| Corium, LLC | $176.14 | 2022-2024 | Azstarys |
| Allergan, INC. | $175.61 | 2019-2020 | |
| Alkermes, INC. | $171.86 | 2022-2025 | Aristada, Lybalvi |
| Eisai INC. | $63.25 | 2020 | |
| Shire North American Group INC | $60.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $54.19 | 2019-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $52.55 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $34.97 | 2020-2024 | Adzenys Xr-Odt |
| Pernix Therapeutics Holdings, INC. | $12.71 | 2019 | |
| Alfasigma USA, INC. | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Imad Khreim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.